Login Register Cart 0
Current Alzheimer Research

Current Alzheimer Research

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Translate in Chinese
Review Article

Recent Advances in the Application of Artificial Intelligence in Alzheimer's Disease

Author(s): Lulu Yao, Jingnian Ni, Mingqing Wei, Ting Li, Fuyao Li, Tuanjie Wang, Wei Xiao, Jing Shi* and Jinzhou Tian*

Volume 22, Issue 11, 2025

Published on: 22 October, 2025

Page: [815 - 827] Pages: 13

DOI: 10.2174/0115672050410489250930175402

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Artificial intelligence (AI) refers to a system that can simulate and execute the processes of human thinking and learning, and make informed decisions. Fueled by the development of AI, the quality and effectiveness of medical work have gained momentum. AI technology plays an increasingly important role in healthcare, exhibiting substantial potential in clinical practice and decision-making processes. In Alzheimer’s disease (AD), where early diagnosis and treatment remain challenging due to clinical heterogeneity and insidious progression, AI could offer excellent solutions. AI models can integrate multi-modal data to identify pre-symptomatic biomarkers and stratify high-risk cohorts, improving diagnostic accuracy, assisting with personalizing treatment and care. Furthermore, AI can accelerate drug discovery and development through drug-target identification and predictive modeling of compound efficacy. However, data quality, supervision, transparency, privacy, and ethical concerns need to be addressed. By identifying and retrieving studies for the systematic review, this article provides a comprehensive overview of current progress and related AI applications in AD.

Keywords: Artificial intelligence, Alzheimer’s disease, neurodegenerative disease, dementia, cognitive function, neuronal loss.

« Previous Next »
[1]
Zheng Q, Wang X. Alzheimer’s disease: Insights into pathology, molecular mechanisms, and therapy. Protein Cell 2025; 16(2): 83-120.
[http://dx.doi.org/10.1093/procel/pwae026] [PMID: 38733347]
[2]
Fang M, Hu J, Weiss J, et al. Lifetime risk and projected burden of dementia. Nat Med 2025; 31(3): 772-6.
[http://dx.doi.org/10.1038/s41591-024-03340-9] [PMID: 39806070]
[3]
Gaugler, J.; James, B.; Johnson, T.; Raimer, J.; Solis, M.; Weuve, J.; Buckley, R.F.; Hohman, T.J. 2022 Alzheimer’s disease facts and figures. Alzheimers Dement 2022; 18(4): 700-89.
[http://dx.doi.org/10.1002/alz.12638] [PMID: 35289055]
[4]
Ahmadi-Abhari S, Brayne C. Descriptive epidemiology of dementia in the US. BMJ 2025; 389: r888.
[http://dx.doi.org/10.1136/bmj.r888] [PMID: 40393744]
[5]
Li X, Feng X, Sun X, Hou N, Han F, Liu Y. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2019. Front Aging Neurosci 2022; 14: 937486.
[http://dx.doi.org/10.3389/fnagi.2022.937486] [PMID: 36299608]
[6]
Gutiérrez IL, Dello Russo C, Novellino F, et al. Noradrenaline in Alzheimer’s Disease: A new potential therapeutic target. Int J Mol Sci 2022; 23(11): 6143.
[http://dx.doi.org/10.3390/ijms23116143] [PMID: 35682822]
[7]
Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018; 14(4): 535-62.
[http://dx.doi.org/10.1016/j.jalz.2018.02.018] [PMID: 29653606]
[8]
Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s disease. Lancet 2021; 397(10284): 1577-90.
[http://dx.doi.org/10.1016/S0140-6736(20)32205-4] [PMID: 33667416]
[9]
Briganti G, Le Moine O. Artificial intelligence in medicine: Today and tomorrow. Front Med 2020; 7: 27.
[http://dx.doi.org/10.3389/fmed.2020.00027] [PMID: 32118012]
[10]
Erickson BJ. Basic artificial intelligence techniques: Machine learning and deep learning. Radiol Clin North Am 2021; 59(6): 933-40.
[http://dx.doi.org/10.1016/j.rcl.2021.06.004] [PMID: 34689878]
[11]
Silver D, Schrittwieser J, Simonyan K, et al. Mastering the game of Go without human knowledge. Nature 2017; 550(7676): 354-9.
[http://dx.doi.org/10.1038/nature24270] [PMID: 29052630]
[12]
Mullard A. What does AlphaFold mean for drug discovery? Nat Rev Drug Discov 2021; 20(10): 725-7.
[http://dx.doi.org/10.1038/d41573-021-00161-0] [PMID: 34522032]
[13]
Kovoor JG, Gupta AK, Bacchi S. ChatGPT: Effective writing is succinct. BMJ 2023; 381: p1125.
[http://dx.doi.org/10.1136/bmj.p1125] [PMID: 37220943]
[14]
Smith J. Daily briefing: The pros and cons of DeepSeek. Nature 2025. [Epub ahead of Print]
[http://dx.doi.org/10.1038/d41586-025-00330-w] [PMID: 39890911]
[15]
Barragán-Montero A, Javaid U, Valdés G, et al. Artificial intelligence and machine learning for medical imaging: A technology review. Phys Med 2021; 83: 242-56.
[http://dx.doi.org/10.1016/j.ejmp.2021.04.016] [PMID: 33979715]
[16]
Choi RY, Coyner AS, Kalpathy-Cramer J, Chiang MF, Campbell JP. Introduction to machine learning, neural networks, and deep learning. Transl Vis Sci Technol 2020; 9(2): 14.
[http://dx.doi.org/10.1167/tvst.9.2.14] [PMID: 32704420]
[17]
Kalpathy-Cramer J, Patel JB, Bridge C, Chang K. Basic artificial intelligence techniques: Evaluation of artificial intelligence performance. Radiol Clin North Am 2021; 59(6): 941-54.
[http://dx.doi.org/10.1016/j.rcl.2021.06.005] [PMID: 34689879]
[18]
Attia ZI, Kapa S, Lopez-Jimenez F, et al. Screening for cardiac contractile dysfunction using an artificial intelligence–enabled electrocardiogram. Nat Med 2019; 25(1): 70-4.
[http://dx.doi.org/10.1038/s41591-018-0240-2] [PMID: 30617318]
[19]
de Grey ADNJ. Artificial intelligence and medical research: Time to aim higher? Rejuvenation Res 2016; 19(2): 105-6.
[http://dx.doi.org/10.1089/rej.2016.1827] [PMID: 26993572]
[20]
Patel MR, Balu S, Pencina MJ. Translating AI for the clinician. JAMA 2024; 332(20): 1701-2.
[http://dx.doi.org/10.1001/jama.2024.21772] [PMID: 39405321]
[21]
Schor NF. Equipping AI for unbiased and inclusive neurology. JAMA Neurol 2025; 82(3): 211–212.
[http://dx.doi.org/10.1001/jamaneurol.2024.3954] [PMID: 39585712]
[22]
Hamet P, Tremblay J. Artificial intelligence in medicine. Metabolism 2017; 69: S36-40.
[http://dx.doi.org/10.1016/j.metabol.2017.01.011] [PMID: 28126242]
[23]
LeCun Y, Bengio Y, Hinton G. Deep learning. Nature 2015; 521(7553): 436-44.
[http://dx.doi.org/10.1038/nature14539] [PMID: 26017442]
[24]
Dorsey ER, Papapetropoulos S, Xiong M, Kieburtz K. The first frontier: Digital biomarkers for neurodegenerative disorders. Digit Biomark 2017; 1(1): 6-13.
[http://dx.doi.org/10.1159/000477383] [PMID: 32095743]
[25]
Piau A, Wild K, Mattek N, Kaye J. Current state of digital biomarker technologies for real-life, home-based monitoring of cognitive function for mild cognitive impairment to mild Alzheimer disease and implications for clinical care: Systematic review. J Med Internet Res 2019; 21(8): e12785.
[http://dx.doi.org/10.2196/12785] [PMID: 31471958]
[26]
Vasudevan S, Saha A, Tarver ME, Patel B. Digital biomarkers: Convergence of digital health technologies and biomarkers. NPJ Digit Med 2022; 5(1): 36.
[http://dx.doi.org/10.1038/s41746-022-00583-z] [PMID: 35338234]
[27]
Gao XR, Chiariglione M, Qin K, et al. Explainable machine learning aggregates polygenic risk scores and electronic health records for Alzheimer’s disease prediction. Sci Rep 2023; 13(1): 450.
[http://dx.doi.org/10.1038/s41598-023-27551-1] [PMID: 36624143]
[28]
Allen B, Agarwal S, Coombs L, Wald C, Dreyer K. 2020 ACR data science institute artificial intelligence survey. J Am Coll Radiol 2021; 18(8): 1153-9.
[http://dx.doi.org/10.1016/j.jacr.2021.04.002] [PMID: 33891859]
[29]
Li L, Xu W, Tan CC, et al. A gene-environment interplay between omega-3 supplementation and APOE ε4 provides insights for Alzheimer’s disease precise prevention amongst high-genetic-risk population. Eur J Neurol 2022; 29(2): 422-31.
[http://dx.doi.org/10.1111/ene.15160] [PMID: 34710256]
[30]
Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet 2024; 404(10452): 572-628.
[http://dx.doi.org/10.1016/S0140-6736(24)01296-0] [PMID: 39096926]
[31]
Long JM, Holtzman DM. Alzheimer disease: An update on pathobiology and treatment strategies. Cell 2019; 179(2): 312-39.
[http://dx.doi.org/10.1016/j.cell.2019.09.001] [PMID: 31564456]
[32]
Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L. Recent advances in Alzheimer’s disease: Mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther 2024; 9(1): 211.
[http://dx.doi.org/10.1038/s41392-024-01911-3] [PMID: 39174535]
[33]
Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet 2019; 51(3): 414-30.
[http://dx.doi.org/10.1038/s41588-019-0358-2] [PMID: 30820047]
[34]
Bellenguez C, Küçükali F, Jansen IE, et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat Genet 2022; 54(4): 412-36.
[http://dx.doi.org/10.1038/s41588-022-01024-z] [PMID: 35379992]
[35]
Sierksma A, Escott-Price V, De Strooper B. Translating genetic risk of Alzheimer’s disease into mechanistic insight and drug targets. Science 2020; 370(6512): 61-6.
[http://dx.doi.org/10.1126/science.abb8575] [PMID: 33004512]
[36]
Leonenko G, Baker E, Stevenson-Hoare J, et al. Identifying individuals with high risk of Alzheimer’s disease using polygenic risk scores. Nat Commun 2021; 12(1): 4506.
[http://dx.doi.org/10.1038/s41467-021-24082-z] [PMID: 34301930]
[37]
Zhou X, Chen Y, Ip FCF, et al. Deep learning-based polygenic risk analysis for Alzheimer’s disease prediction. Commun Med 2023; 3(1): 49.
[http://dx.doi.org/10.1038/s43856-023-00269-x] [PMID: 37024668]
[38]
Wei W, Visweswaran S, Cooper GF. The application of naive Bayes model averaging to predict Alzheimer’s disease from genome-wide data. J Am Med Inform Assoc 2011; 18(4): 370-5.
[http://dx.doi.org/10.1136/amiajnl-2011-000101] [PMID: 21672907]
[39]
Lundberg M, Sng LMF, Szul P, et al. Novel Alzheimer’s disease genes and epistasis identified using machine learning GWAS platform. Sci Rep 2023; 13(1): 17662.
[http://dx.doi.org/10.1038/s41598-023-44378-y] [PMID: 37848535]
[40]
Shigemizu D, Akiyama S, Suganuma M, et al. Classification and deep-learning–based prediction of Alzheimer disease subtypes by using genomic data. Transl Psychiatry 2023; 13(1): 232.
[http://dx.doi.org/10.1038/s41398-023-02531-1] [PMID: 37386009]
[41]
Xie Z, Situ Y, Deng L, et al. Identification of therapeutic targets for Alzheimer’s Disease Treatment using bioinformatics and machine learning. Sci Rep 2025; 15(1): 3888.
[http://dx.doi.org/10.1038/s41598-025-88134-w] [PMID: 39890844]
[42]
Kivimäki M, Livingston G, Singh-Manoux A, et al. Estimating dementia risk using multifactorial prediction models. JAMA Netw Open 2023; 6(6): e2318132.
[http://dx.doi.org/10.1001/jamanetworkopen.2023.18132] [PMID: 37310738]
[43]
Ferreira PCL, Zhang Y, Snitz B, et al. Plasma biomarkers identify older adults at risk of Alzheimer’s disease and related dementias in a real-world population-based cohort. Alzheimers Dement 2023; 19(10): 4507-19.
[http://dx.doi.org/10.1002/alz.12986] [PMID: 36876954]
[44]
You J, Zhang YR, Wang HF, et al. Development of a novel dementia risk prediction model in the general population: A large, longitudinal, population-based machine-learning study. EClin Med 2022; 53: 101665.
[http://dx.doi.org/10.1016/j.eclinm.2022.101665] [PMID: 36187723]
[45]
Tang AS, Rankin KP, Cerono G, et al. Leveraging electronic health records and knowledge networks for Alzheimer’s disease prediction and sex-specific biological insights. Nature Aging 2024; 4(3): 379-95.
[http://dx.doi.org/10.1038/s43587-024-00573-8] [PMID: 38383858]
[46]
Duara R, Barker W. Heterogeneity in Alzheimer’s disease diagnosis and progression rates: Implications for therapeutic trials. Neurotherapeutics 2022; 19(1): 8-25.
[http://dx.doi.org/10.1007/s13311-022-01185-z] [PMID: 35084721]
[47]
Kovacs GG. Clinical stratification of subtypes of Alzheimer’s disease. Lancet Neurol 2012; 11(10): 839-41.
[http://dx.doi.org/10.1016/S1474-4422(12)70209-0] [PMID: 22995685]
[48]
Patil S, Kukreja S. Early detection of cognitive decline with deep learning and graph-based modeling. MethodsX 2025; 14: 103405.
[http://dx.doi.org/10.1016/j.mex.2025.103405] [PMID: 40567946]
[49]
Topol E. Predicting and preventing Alzheimer’s disease. Science 2025; 388(6750): eady3217.
[http://dx.doi.org/10.1126/science.ady3217] [PMID: 40440380]
[50]
Saleem TJ, Zahra SR, Wu F, et al. Deep learning-based diagnosis of Alzheimer’s disease. J Pers Med 2022; 12(5): 815.
[http://dx.doi.org/10.3390/jpm12050815] [PMID: 35629237]
[51]
Márquez F, Yassa MA. Neuroimaging biomarkers for Alzheimer’s disease. Mol Neurodegener 2019; 14(1): 21.
[http://dx.doi.org/10.1186/s13024-019-0325-5] [PMID: 31174557]
[52]
Kang J, Caffo B, Liu H. Editorial: Recent advances and challenges on big data analysis in neuroimaging. Front Neurosci 2016; 10: 505.
[http://dx.doi.org/10.3389/fnins.2016.00505] [PMID: 27895547]
[53]
Etminani K, Soliman A, Davidsson A, et al. A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer’s disease, and mild cognitive impairment using brain 18F-FDG PET. Eur J Nucl Med Mol Imaging 2022; 49(2): 563-84.
[http://dx.doi.org/10.1007/s00259-021-05483-0] [PMID: 34328531]
[54]
Zhu W, Sun L, Huang J, Han L, Zhang D. Dual attention multi-instance deep learning for Alzheimer’s disease diagnosis with structural MRI. IEEE Trans Med Imaging 2021; 40(9): 2354-66.
[http://dx.doi.org/10.1109/TMI.2021.3077079] [PMID: 33939609]
[55]
Hassan N, Miah ASM, Suzuki K, Okuyama Y, Shin J. Stacked CNN-based multichannel attention networks for Alzheimer disease detection. Sci Rep 2025; 15(1): 5815.
[http://dx.doi.org/10.1038/s41598-025-85703-x] [PMID: 39962097]
[56]
Kim JS, Han JW, Bae JB, et al. Deep learning-based diagnosis of Alzheimer’s disease using brain magnetic resonance images: An empirical study. Sci Rep 2022; 12(1): 18007.
[http://dx.doi.org/10.1038/s41598-022-22917-3] [PMID: 36289390]
[57]
de Vries BM, Golla SSV, Ebenau J, et al. Classification of negative and positive 18F-florbetapir brain PET studies in subjective cognitive decline patients using a convolutional neural network. Eur J Nucl Med Mol Imaging 2021; 48(3): 721-8.
[http://dx.doi.org/10.1007/s00259-020-05006-3] [PMID: 32875431]
[58]
Rakvongthai Y, Patipipittana S. AI-powered FDG-PET radiomics: A door to better Alzheimer’s disease classification? Eur Radiol 2025; 35(5): 2617-9.
[http://dx.doi.org/10.1007/s00330-025-11381-y] [PMID: 39870903]
[59]
Fan S, Ponisio MR, Xiao P, et al. AmyloidPETNet: Classification of amyloid positivity in brain PET imaging using end-to-end deep learning. Radiology 2024; 311(3): e231442.
[http://dx.doi.org/10.1148/radiol.231442] [PMID: 38860897]
[60]
Ye B, Chu CH, Bayat S, Babineau J, How TV, Mihailidis A. Researched apps used in dementia care for people living with dementia and their informal caregivers: Systematic review on app features, security, and usability. J Med Internet Res 2023; 25: e46188.
[http://dx.doi.org/10.2196/46188] [PMID: 37824187]
[61]
El-Sappagh S, Alonso JM, Islam SMR, Sultan AM, Kwak KS. A multilayer multimodal detection and prediction model based on explainable artificial intelligence for Alzheimer’s disease. Sci Rep 2021; 11(1): 2660.
[http://dx.doi.org/10.1038/s41598-021-82098-3] [PMID: 33514817]
[62]
Bucholc M, Ding X, Wang H, et al. A practical computerized decision support system for predicting the severity of Alzheimer’s disease of an individual. Expert Syst Appl 2019; 130: 157-71.
[http://dx.doi.org/10.1016/j.eswa.2019.04.022] [PMID: 31402810]
[63]
Lin W, Gao Q, Yuan J, et al. Predicting Alzheimer’s disease conversion from mild cognitive impairment using an extreme learning machine-based grading method with multimodal data. Front Aging Neurosci 2020; 12: 77.
[http://dx.doi.org/10.3389/fnagi.2020.00077] [PMID: 32296326]
[64]
Buchman AS, Bennett DA. Loss of motor function in preclinical Alzheimer’s disease. Expert Rev Neurother 2011; 11(5): 665-76.
[http://dx.doi.org/10.1586/ern.11.57] [PMID: 21539487]
[65]
Yan JH, Rountree S, Massman P, Doody RS, Li H. Alzheimer’s disease and mild cognitive impairment deteriorate fine movement control. J Psychiatr Res 2008; 42(14): 1203-12.
[http://dx.doi.org/10.1016/j.jpsychires.2008.01.006] [PMID: 18280503]
[66]
Qi Y, Zhu X, Xiong X, et al. Human motor cortex encodes complex handwriting through a sequence of stable neural states. Nat Hum Behav 2025; 9(6): 1260-71.
[http://dx.doi.org/10.1038/s41562-025-02157-x] [PMID: 40175631]
[67]
Sweidan J, El-Yacoubi MA, Rigaud AS. Explainability of CNN-based Alzheimer’s disease detection from online handwriting. Sci Rep 2024; 14(1): 22108.
[http://dx.doi.org/10.1038/s41598-024-72650-2] [PMID: 39333681]
[68]
Nardone E, De Stefano C, Cilia ND, Fontanella F. Handwriting strokes as biomarkers for Alzheimer’s disease prediction: A novel machine learning approach. Comput Biol Med 2025; 190: 110039.
[http://dx.doi.org/10.1016/j.compbiomed.2025.110039] [PMID: 40158458]
[69]
Hao J, Kwapong WR, Shen T, et al. Early detection of dementia through retinal imaging and trustworthy AI. NPJ Digit Med 2024; 7(1): 294.
[http://dx.doi.org/10.1038/s41746-024-01292-5] [PMID: 39428420]
[70]
Cheung CY, Ran AR, Wang S, et al. A deep learning model for detection of Alzheimer’s disease based on retinal photographs: a retrospective, multicentre case-control study. Lancet Digit Health 2022; 4(11): e806-15.
[http://dx.doi.org/10.1016/S2589-7500(22)00169-8] [PMID: 36192349]
[71]
Acharya M, Deo RC, Tao X, et al. Deep learning techniques for automated Alzheimer’s and mild cognitive impairment disease using EEG signals: A comprehensive review of the last decade (2013 - 2024). Comput Methods Programs Biomed 2025; 259: 108506.
[http://dx.doi.org/10.1016/j.cmpb.2024.108506] [PMID: 39581069]
[72]
Tröger J, Linz N, König A, et al. Exploitation vs. exploration - computational temporal and semantic analysis explains semantic verbal fluency impairment in Alzheimer’s disease. Neuropsychologia 2019; 131: 53-61.
[http://dx.doi.org/10.1016/j.neuropsychologia.2019.05.007] [PMID: 31121184]
[73]
Chimamiwa G, Giaretta A, Alirezaie M, Pecora F, Loutfi A. Are smart homes adequate for older adults with dementia? Sensors 2022; 22(11): 4254.
[http://dx.doi.org/10.3390/s22114254] [PMID: 35684874]
[74]
Possin KL, Burns JM, Forester BP. Collaborative dementia care during the new therapeutic era. JAMA Neurol 2024; 81(12): 1241-2.
[http://dx.doi.org/10.1001/jamaneurol.2024.3379] [PMID: 39401023]
[75]
Shu S, Woo BKP. Use of technology and social media in dementia care: Current and future directions. World J Psychiatry 2021; 11(4): 109-23.
[http://dx.doi.org/10.5498/wjp.v11.i4.109] [PMID: 33889536]
[76]
Moon S, Park K. The effect of digital reminiscence therapy on people with dementia: A pilot randomized controlled trial. BMC Geriatr 2020; 20(1): 166.
[http://dx.doi.org/10.1186/s12877-020-01563-2] [PMID: 32375661]
[77]
Hussain M, Ali T, Khan WA, Afzal M, Lee S, Latif K. Recommendations service for chronic disease patient in multimodel sensors home environment. Telemed J E Health 2015; 21(3): 185-99.
[http://dx.doi.org/10.1089/tmj.2014.0028] [PMID: 25559934]
[78]
Thyrian JR, Hertel J, Wucherer D, et al. Effectiveness and safety of dementia care management in primary care. JAMA Psychiatry 2017; 74(10): 996-1004.
[http://dx.doi.org/10.1001/jamapsychiatry.2017.2124] [PMID: 28746708]
[79]
Hasan WU, Zaman KT, Wang X, Li J, Xie B, Tao C. Empowering Alzheimer’s caregivers with conversational AI: A novel approach for enhanced communication and personalized support. npj Biomed Innov 2024; 1(1): 3.
[http://dx.doi.org/10.1038/s44385-024-00004-8]
[80]
Vatansever S, Schlessinger A, Wacker D, et al. Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions. Med Res Rev 2021; 41(3): 1427-73.
[http://dx.doi.org/10.1002/med.21764] [PMID: 33295676]
[81]
Tsuji S, Hase T, Yachie-Kinoshita A, et al. Artificial intelligence-based computational framework for drug-target prioritization and inference of novel repositionable drugs for Alzheimer’s disease. Alzheimers Res Ther 2021; 13(1): 92.
[http://dx.doi.org/10.1186/s13195-021-00826-3] [PMID: 33941241]
[82]
Wu T, Lin R, Cui P, Yong J, Yu H, Li Z. Deep learning-based drug screening for the discovery of potential therapeutic agents for Alzheimer’s disease. J Pharm Anal 2024; 14(10): 101022.
[http://dx.doi.org/10.1016/j.jpha.2024.101022] [PMID: 39850238]
[83]
Das B, Mathew AT, Baidya ATK, Devi B, Salmon RR, Kumar R. Artificial intelligence assisted identification of potential tau aggregation inhibitors: Ligand- and structure-based virtual screening, in silico ADME, and molecular dynamics study. Mol Divers 2024; 28(4): 2013-31.
[http://dx.doi.org/10.1007/s11030-023-10645-3] [PMID: 37022608]
[84]
Xie C, Zhuang XX, Niu Z, et al. Amelioration of Alzheimer’s disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow. Nat Biomed Eng 2022; 6(1): 76-93.
[http://dx.doi.org/10.1038/s41551-021-00819-5] [PMID: 34992270]
[85]
Vaghari D, Mohankumar G, Tan K, et al. AI-guided patient stratification improves outcomes and efficiency in the AMARANTH Alzheimer’s Disease clinical trial. Nat Commun 2025; 16(1): 6244.
[http://dx.doi.org/10.1038/s41467-025-61355-3] [PMID: 40675957]
[86]
Zulhafiz NA, Teoh TC, Chin AV, Chang SW. Drug repurposing using artificial intelligence, molecular docking, and hybrid approaches: A comprehensive review in general diseases vs Alzheimer’s disease. Comput Methods Programs Biomed 2025; 261: 108604.
[http://dx.doi.org/10.1016/j.cmpb.2025.108604] [PMID: 39826482]
[87]
Yan C, Grabowska ME, Dickson AL, et al. Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer’s disease with real-world clinical validation. NPJ Digit Med 2024; 7(1): 46.
[http://dx.doi.org/10.1038/s41746-024-01038-3] [PMID: 38409350]
[88]
Grabowska ME, Huang A, Wen Z, Li B, Wei WQ. Drug repurposing for Alzheimer’s disease from 2012–2022 - A 10-year literature review. Front Pharmacol 2023; 14: 1257700.
[http://dx.doi.org/10.3389/fphar.2023.1257700] [PMID: 37745051]
[89]
Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: Progress, challenges and recommendations. Nat Rev Drug Discov 2019; 18(1): 41-58.
[http://dx.doi.org/10.1038/nrd.2018.168] [PMID: 30310233]
[90]
Fang J, Zhang P, Wang Q, et al. Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease. Alzheimers Res Ther 2022; 14(1): 7.
[http://dx.doi.org/10.1186/s13195-021-00951-z] [PMID: 35012639]
[91]
Qiu Y, Cheng F. Artificial intelligence for drug discovery and development in Alzheimer’s disease. Curr Opin Struct Biol 2024; 85: 102776.
[http://dx.doi.org/10.1016/j.sbi.2024.102776] [PMID: 38335558]
[92]
Withers CA, Rufai AM, Venkatesan A, et al. Natural language processing in drug discovery: Bridging the gap between text and therapeutics with artificial intelligence. Expert Opin Drug Discov 2025; 20(6): 765-83.
[http://dx.doi.org/10.1080/17460441.2025.2490835] [PMID: 40298230]
[93]
AI’s potential to accelerate drug discovery needs a reality check. Nature 2023; 622(7982): 217.
[http://dx.doi.org/10.1038/d41586-023-03172-6] [PMID: 37817040]
[94]
Li Z, Jiang X, Wang Y, Kim Y. Applied machine learning in Alzheimer’s disease research: Omics, imaging, and clinical data. Emerg Top Life Sci 2021; 5(6): 765-77.
[http://dx.doi.org/10.1042/ETLS20210249] [PMID: 34881778]
[95]
Beheshti I, Albensi BC, Freitas A, Ghafourian T. Advancements and challenges in using AI for biomarker detection in early Alzheimer’s disease. Drug Discov Today 2025; 30(7): 104415.
[http://dx.doi.org/10.1016/j.drudis.2025.104415] [PMID: 40545029]
[96]
van der Flier WM, de Vugt ME, Smets EMA, Blom M, Teunissen CE. Towards a future where Alzheimer’s disease pathology is stopped before the onset of dementia. Nature Aging 2023; 3(5): 494-505.
[http://dx.doi.org/10.1038/s43587-023-00404-2] [PMID: 37202515]
[97]
Weiner MW, Veitch DP, Aisen PS, et al. The Alzheimer’s disease neuroimaging initiative 3: Continued innovation for clinical trial improvement. Alzheimers Dement 2017; 13(5): 561-71.
[http://dx.doi.org/10.1016/j.jalz.2016.10.006] [PMID: 27931796]
[98]
Qi W, Zhu X, He D, et al. Mapping knowledge landscapes and emerging trends in AI for dementia biomarkers: Bibliometric and visualization analysis. J Med Internet Res 2024; 26: e57830.
[http://dx.doi.org/10.2196/57830] [PMID: 39116438]
[99]
Finlayson SG, Subbaswamy A, Singh K, et al. The clinician and dataset shift in artificial intelligence. N Engl J Med 2021; 385(3): 283-6.
[http://dx.doi.org/10.1056/NEJMc2104626] [PMID: 34260843]
[100]
Lyall DM, Kormilitzin A, Lancaster C, et al. Artificial intelligence for dementia - Applied models and digital health. Alzheimers Dement 2023; 19(12): 5872-84.
[http://dx.doi.org/10.1002/alz.13391] [PMID: 37496259]
[101]
Li Q, Yang MQ. Comparison of machine learning approaches for enhancing Alzheimer’s disease classification. PeerJ 2021; 9: e10549.
[http://dx.doi.org/10.7717/peerj.10549] [PMID: 33665002]
[102]
Khera R, Butte AJ, Berkwits M, et al. AI in medicine-JAMA's focus on clinical outcomes, patient-centered care, quality, and equity. JAMA 2023; 330(9): 818-20.
[http://dx.doi.org/10.1001/jama.2023.15481] [PMID: 37566406]
[103]
Bengio Y, Hinton G, Yao A, et al. Managing extreme AI risks amid rapid progress. Science 2024; 384(6698): 842-5.
[http://dx.doi.org/10.1126/science.adn0117] [PMID: 38768279]
[104]
Khalid N, Qayyum A, Bilal M, Al-Fuqaha A, Qadir J. Privacy-preserving artificial intelligence in healthcare: Techniques and applications. Comput Biol Med 2023; 158: 106848.
[http://dx.doi.org/10.1016/j.compbiomed.2023.106848] [PMID: 37044052]

Rights & Permissions Print Cite
Article Metrics
Pdf icon 33
Html icon 3
Find your institution